Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

342
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
342
Gene Therapy00:59

Gene Therapy

25.5K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.5K
Antibody Structure01:10

Antibody Structure

60.3K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.3K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

487
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
487
Tumor Immunotherapy01:27

Tumor Immunotherapy

555
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
555
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

442
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
442

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of population-specific pharmacogenomic variants on drug dosing in ICU patients.

The pharmacogenomics journal·2026
Same author

Genes required for <i>Mycobacterium tuberculosis</i> to survive the transition from aerosol to pulmonary alveolar lining fluid and early infection in a model of transmission.

bioRxiv : the preprint server for biology·2025
Same author

Twenty-Year Survival Analysis of Adeno-Associated Virus Vector Serotype 2-Mediated Gene Therapy to the Central Nervous System for CLN2 Disease.

Human gene therapy·2025
Same author

Vectorized Human Antibody-Mediated Anti-Eosinophil Gene Therapy.

Human gene therapy·2024
Same author

Suppression of CNS APOE4 Expression by miRNAs Delivered by the S2 AAVrh.10 Capsid-Modified AAV Vector.

Human gene therapy·2024
Same author

Positron Emission Tomography Quantitative Assessment of Off-Target Whole-Body Biodistribution of I-124-Labeled Adeno-Associated Virus Capsids Administered to Cerebral Spinal Fluid.

Human gene therapy·2023

Related Experiment Video

Updated: Jul 17, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

804

Gene Therapy for Immunoglobulin E, Complement-Mediated, and Eosinophilic Disorders.

Odelya E Pagovich1, Ronald G Crystal1

  • 1Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA.

Human Gene Therapy
|September 6, 2023
PubMed
Summary

Gene therapy and antisense technology offer novel ways to treat human disorders by modulating key immune components. These advanced techniques target immunoglobulin E, complement, and eosinophils for therapeutic benefit.

Keywords:
allergycomplementeosinophilgene therapy

More Related Videos

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

18.5K
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

16.4K

Related Experiment Videos

Last Updated: Jul 17, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

804
Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

18.5K
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

16.4K

Area of Science:

  • Immunology and Genetics
  • Therapeutic Technologies

Background:

  • Immunoglobulin E (IgE), complement, and eosinophils are crucial for host defense.
  • Dysfunction in these immune components can precipitate various human diseases.

Purpose of the Study:

  • To review the application of gene therapy and antisense technology in managing immune-related disorders.
  • To explore methods for modulating IgE, complement, and eosinophil levels.

Main Methods:

  • Literature review of gene therapy and antisense technology applications.
  • Analysis of studies focusing on immune component modulation.

Main Results:

  • Gene therapy and antisense approaches show promise in regulating IgE, complement, and eosinophil levels.
  • These technologies offer potential treatment avenues for associated human disorders.

Conclusions:

  • Gene therapy and antisense technology represent innovative strategies for treating immune dysfunction.
  • Targeting IgE, complement, and eosinophils provides a pathway for novel therapeutic development.